Novo Nordisk Rolls Out Wegovy Oral Pill with $149 Starter Dose, $25 Insured Price
Novo Nordisk launched the FDA-approved Wegovy oral weight-loss pill in US pharmacies with a 1.5mg dose at $149/month; insured patients pay as little as $25/month. Shares trade above 20- and 50-day SMAs but sit 8.4% below the 200-day SMA, with RSI near 60 and bullish MACD indicating upside potential.
1. U.S. Launch Spurs Significant Share Gains
Novo Nordisk’s announcement that its first oral GLP-1 weight-loss therapy received FDA approval and is now available in U.S. pharmacies triggered a 17% rally in the company’s shares over the past month. Investors responded enthusiastically to the potential for Wegovy™ pill to capture new patient segments who prefer oral medication, boosting trading volumes by nearly 30% on launch day and narrowing the gap between current valuation and last year’s 52-week high of 94.
2. Strong Clinical Profile Underpins Market Potential
In phase III trials, patients receiving the Wegovy pill alongside diet and exercise achieved an average weight reduction of 16.6%, compared with just 2.7% for placebo when accounting for full adherence. An intent-to-treat analysis showed a 13.6% loss versus 2.4% for placebo, demonstrating durable efficacy even with discontinuations. With four dosage strengths approved—1.5 mg, 4 mg, 9 mg and 25 mg—Novo Nordisk has structured pricing to start at $149 per month for self-pay patients, offering multiple affordability programs and targeting an addressable U.S. market projected to exceed $30 billion by 2030.
3. Technical Indicators Suggest Cautious Optimism
Technical analysis highlights that the stock is trading above its 20- and 50-day moving averages, signaling short-term momentum, while it remains approximately 8.4% below its 200-day trend line, reflecting longer-term consolidation. The relative strength index sits near 60, indicating neither overbought nor oversold conditions, and the MACD has crossed above its signal line, pointing to bullish momentum. Key chart levels include support around the mid-forties and resistance near the upper fifties, suggesting potential reaction points for risk-aware investors.
4. Competitive Dynamics and Future Catalysts
Novo Nordisk’s early entry into the oral GLP-1 segment positions it against rivals, notably Eli Lilly’s forthcoming oral candidate with fewer dietary restrictions. The company’s ability to leverage its established supply chain, broaden patient access through telehealth and retail partnerships, and advance combination therapies in its pipeline will be critical. Upcoming earnings releases, real-world adoption data and potential label expansions—such as cardiovascular risk reduction—represent key catalysts for sustaining share price momentum into 2026.